Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

19 Mar 2020

Abstract excerpt

Combined PARP and immune checkpoint inhibition has yielded encouraging results in ovarian cancer, but predictive biomarkers are lacking. We performed immunogenomic profiling and highly multiplexed single-cell imaging on tumor samples from patients enrolled in a Phase I/II trial of niraparib and pembrolizumab in ovarian cancer (NCT02657889). We identify two determinants of response; mutational signature 3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32193378
DOI: 10.1038/s41467-020-15315-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerPMID 32193378Read ↗

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsSemantic proximity Read ↗

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.Semantic proximity Read ↗

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancerSemantic proximity Read ↗

Single-Cell Approaches to Profile the Response to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.Semantic proximity Read ↗

Patient-derived functional immuno-oncology platform identifies responders to ATR inhibitor and immunotherapy combinations in ovarian cancerSemantic proximity Read ↗

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancerSemantic proximity Read ↗

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trialsSemantic proximity Read ↗

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trialsSemantic proximity Read ↗

Delineating spatial cell-cell interactions in the solid tumour microenvironment through the lens of highly multiplexed imagingSemantic proximity Read ↗

Single-Cell Analysis Technologies for Immuno-Oncology Research: From Mechanistic Delineation to Biomarker DiscoverySemantic proximity Read ↗

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.